Intensive Care Medicine

, Volume 42, Issue 4, pp 491–493 | Cite as

Focus on infection and sepsis in intensive care patients

  • Ignacio Martin-LoechesEmail author
  • Anders Perner
Focus Editorial

Over the last year, several papers have shed light on the management of severe infections and sepsis in intensive care units (ICU). With this overview, we will highlight the important new findings with a focus on infectious disease and sepsis in critically ill patients.

The concept of healthcare-associated pneumonia (HCAP) tried to highlight the increasing prevalence of multidrug-resistant pathogens [1]. The majority of the studies have been conducted outside Europe. Vallés et al. conducted a prospective, multicentre study in Spain [2] in which the etiology of community-acquired pneumonia (CAP) and HCAP was comparable, as S. pneumoniae was the most frequently found pathogen. Therefore, based on this European study, empirical antibiotic therapy recommended for CAP would be appropriate for 90 % of patients with HCAP, at least in that population, and clearly differs from experiences in countries with higher rates of resistant pathogens.

One important element over the last year in infectious diseases in critically ill patients has been the development of both less invasive and more sensitive diagnostic techniques in pneumonia [3]. A “What’s new in intensive care” paper highlighted the innovative technologies that could result in a more timely recognition of respiratory infections [4] in critically ill patients through the detection of bacterial colonization (colorimetric endotracheal tubes) and the interaction between bacterial growth and host response (exhaled breath analysis) [5]. These technologies are still promising but not fully validated yet. Another promising area of research is the right use of biomarkers [6] in either decision-based algorithms like CHAID (Chi-squared Automatic Interaction Detection) [7] or biomarker combinations to increase diagnostic accuracy [8].

An important “My paper 10 years later” described the trends in infective endocarditis in the ICU [9]. The authors pointed to sustained high mortality rates in patients with infective endocarditis, rates that may exceed 60 % mortality in ICU. They suggested a standardized approach to bacteriological testing including broad-range polymerase chain reaction (PCR) because of the high rates of culture-negative bacteraemia. SeptiFast is the first real-time PCR-based system and, to date, the most intensively investigated in clinical cohort studies. To this end, two papers have provided evidence regarding the new rapid diagnostic tests in bacteraemia. Warhurst et al. [10] conducted a phase III prospective multicentre diagnostic accuracy study of SeptiFast against microbiological culture in critical care settings. SeptiFast had a significantly greater specificity (0.86) than sensitivity (0.50) for bacteraemia. The most interesting finding was that despite the potential benefit of such a technique, there was a low prevalence of blood culture-proven pathogens (9.2 %), acknowledging the potential limitations of this technology in diagnosing bloodstream infection when compared with bloodstream infection at the species/genus level. An updated systematic review and meta-analysis [11], including this study, concluded that standard blood culture techniques are currently not a perfect reference standard, but it is the one that has been used as the basis for the SeptiFast platform design (pathogen panel spectrum designed on the basis of the most common bloodstream infection globally) and it has inevitably influenced subsequent clinical diagnostic trials internationally. The main conclusion is that there is a higher specificity than sensitivity compared to blood cultures, but SeptiFast is not ready for implementation in clinical practice. An appraisal for the future would be the incorporation of a wider test panel of pathogens, which may be expected to provide greater diagnostic sensitivity (fewer false negative results). The latter could give clinicians greater confidence in a rapid negative test result, which may lead to reduced use of antibiotics.

In regard to fungal infections in critically ill patients, the vast majority of the recent papers were developed in Europe and the USA. A multicentre study on ICU-acquired candidemia in India [12] reported 6.51 cases per 1000 ICU admissions with high prevalence of C. tropicalis. This is in contrast to the developed world, where C. tropicalis is uniformly less common and C. albicans and C. glabrata are more prevalent. The report showed a higher proportion of patients who developed candidemia in Brazil [13]; however, the mortality rate of candidemia in ICU patients decreased in recent years. In this cohort, the receipt of an echinocandin as primary therapy was associated with lower 30-day mortality. Interestingly, Bassetti et al. [14] conducted a retrospective multinational study of intra-abdominal candidiasis and found low percentages of concomitant candidemia; however, the mortality rate was high in ICU (39 %). Interestingly, echinocandins were prescribed in two-thirds of the patients included in that study. Whilst this may be appropriate, the main problem is the difficulties in determining true infection and when to de-escalate antimycotic agents. Regarding the first point, Martín-Mazuelos et al. [15] conducted a prospective cohort of 107 unselected, non-neutropenic ICU patients and found that (1→3)-β-d-glucan (BDG) levels were higher in patients with invasive candidiasis and high-grade candida colonization. Two consecutive BDG levels ≥80 pg/mL allowed discrimination between invasive candidiasis and high-grade colonization; however, the AUROC for either BDG or C. albicans germ tube antibody (CAGTA) was low (0.67 and 0.55 respectively). Regarding antifungal de-escalation, Bailly et al. [16] found that de-escalation was uncommon (occurred in only 22 % of cases) and was not associated with increased 28-day mortality; it did significantly decrease the use of antifungal agents in invasive candidiasis in non-neutropenic ICU patients.

Up to 70 % of antifungal therapy ordered in the ICU is pre-emptive/empirical [14], most likely because of the diagnostic difficulties of invasive candidiasis and the fact that delays in starting appropriate antifungal treatment have been associated with increased mortality in patients with candidemia [17]. In a recent study, Ferreira et al. [18] found that a pre-emptive strategy of antifungal increased C. glabrata colonization without a significant shift of colonization to other Candida spp. The results of two recent studies may help clinicians to better understand candida isolates in respiratory samples. Terraneo et al. [19] found that antifungal treatment for patients with Candida spp. isolates in airways in patients with hospital-acquired pneumonia admitted to ICU did not influence outcome. Similar results were confirmed by Albert et al. [20] in a multicentre double-blinded, placebo-controlled, pilot randomized trial of antifungal therapy in critically ill patients with clinical suspicion of ventilator-associated pneumonia and positive airway secretion specimens for Candida spp.


  1. 1.
    Martin-Loeches I, Torres A, Rinaudo M et al (2015) Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organi. J Infect 70:213–222. doi: 10.1016/j.jinf.2014.10.004 CrossRefPubMedGoogle Scholar
  2. 2.
    Vallés J, Martin-Loeches I, Torres A et al (2014) Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. Intensive Care Med. doi: 10.1007/s00134-014-3239-2 PubMedGoogle Scholar
  3. 3.
    Nair GB, Niederman MS (2015) Ventilator-associated pneumonia: present understanding and ongoing debates. Intensive Care Med 41:34–48. doi: 10.1007/s00134-014-3564-5 CrossRefPubMedGoogle Scholar
  4. 4.
    Martin-Loeches I, Povoa P, Rodríguez A et al (2015) Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study. Lancet Respir Med 3:859–868. doi: 10.1016/S2213-2600(15)00326-4 CrossRefPubMedGoogle Scholar
  5. 5.
    Bos LDJ, Martin-Loeches I, Artigas A (2014) Innovations that could improve early recognition of ventilator-associated pneumonia. Intensive Care Med 40:1352–1354Google Scholar
  6. 6.
    Albrich WC, Harbarth S (2015) Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting. Intensive Care Med 41:1739–1751. doi: 10.1007/s00134-015-3978-8 CrossRefPubMedGoogle Scholar
  7. 7.
    Rodríguez AH, Avilés-Jurado FX, Díaz E et al (2015) Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: a CHAID decision-tree analysis. J Infect. doi: 10.1016/j.jinf.2015.11.007 Google Scholar
  8. 8.
    Martin-Loeches I, Bos LD, Povoa P et al (2015) Tumor necrosis factor receptor 1 (TNFRI) for ventilator-associated pneumonia diagnosis by cytokine multiplex analysis. Intensive Care Med Exp 3:26. doi: 10.1186/s40635-015-0062-1 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wolff M, Mourvillier B, Sonneville R, Timsit J-F (2014) My paper 10 years later: infective endocarditis in the intensive care unit. Intensive Care Med 40:1843–1852. doi: 10.1007/s00134-014-3490-6 CrossRefPubMedGoogle Scholar
  10. 10.
    Warhurst G, Maddi S, Dunn G et al (2015) Diagnostic accuracy of SeptiFast multi-pathogen real-time PCR in the setting of suspected healthcare-associated bloodstream infection. Intensive Care Med 41:86–93. doi: 10.1007/s00134-014-3551-x CrossRefPubMedGoogle Scholar
  11. 11.
    Dark P, Blackwood B, Gates S et al (2015) Accuracy of LightCycler® SeptiFast for the detection and identification of pathogens in the blood of patients with suspected sepsis: a systematic review and meta-analysis. Intensive Care Med 41:21–33. doi: 10.1007/s00134-014-3553-8 CrossRefPubMedGoogle Scholar
  12. 12.
    Chakrabarti A, Sood P, Rudramurthy SM et al (2015) Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 41:285–295. doi: 10.1007/s00134-014-3603-2 CrossRefPubMedGoogle Scholar
  13. 13.
    Colombo AL, Guimarães T, Sukienik T et al (2014) Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med 40:1489–1498. doi: 10.1007/s00134-014-3400-y CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Bassetti M, Righi E, Ansaldi F et al (2015) A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med 41:1601–1610. doi: 10.1007/s00134-015-3866-2 CrossRefPubMedGoogle Scholar
  15. 15.
    Martín-Mazuelos E, Loza A, Castro C et al (2015) β-d-Glucan and Candida albicans germ tube antibody in ICU patients with invasive candidiasis. Intensive Care Med 41:1424–1432. doi: 10.1007/s00134-015-3922-y CrossRefPubMedGoogle Scholar
  16. 16.
    Bailly S, Leroy O, Montravers P et al (2015) Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data. Intensive Care Med 41:1931–1940. doi: 10.1007/s00134-015-4053-1 CrossRefPubMedGoogle Scholar
  17. 17.
    León C, Ostrosky-Zeichner L, Schuster M (2014) What’s new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. Intensive Care Med 40:808–819. doi: 10.1007/s00134-014-3281-0 CrossRefPubMedGoogle Scholar
  18. 18.
    Ferreira D, Grenouillet F, Blasco G et al (2015) Outcomes associated with routine systemic antifungal therapy in critically ill patients with Candida colonization. Intensive Care Med 41:1077–1088. doi: 10.1007/s00134-015-3791-4 CrossRefPubMedGoogle Scholar
  19. 19.
    Terraneo S, Ferrer M, Martín-Loeches I et al (2015) Impact of Candida spp. isolation in the respiratory tract in patients with intensive care unit-acquired pneumonia. Clin Microbiol Infect. doi: 10.1016/j.cmi.2015.09.002 PubMedGoogle Scholar
  20. 20.
    Albert M, Williamson D, Muscedere J et al (2014) Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Med 40:1313–1322. doi: 10.1007/s00134-014-3352-2 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg and ESICM 2016

Authors and Affiliations

  1. 1.Multidisciplinary Intensive Care Research Organization (MICRO), Department of Clinical Medicine, Trinity Centre for Health Sciences. The Wellcome Trust – HRB Dublin Centre for Clinical Research (DCCR)St James’s University HospitalDublin 8Ireland
  2. 2.CIBER Enfermedades Respiratorias (CIBERES)BarcelonaSpain
  3. 3.Department of Intensive Care, RigshospitaletUniversity of CopenhagenCopenhagenDenmark

Personalised recommendations